Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART105 in healthy adult participants
NCT07748026Phase 1Not yet recruiting
- Sponsor
- Arnatar Therapeutics
- Start
- Aug 2026
- Primary completion
- Feb 2027
01
Overview
Phase 1, randomised, double-blind trial of ART105 in autosomal dominant polycystic kidney disease (ADPKD) (4 arms), sponsored by Arnatar Therapeutics. Primary endpoint: Incidence of Adverse Events at Day 85. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ART105
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT07748026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748026.